Dapagliflozin recommended for approval in Europe

Friday 20 April 2012

Dapagliflozin, a treatment for Type 2 diabetes that has been co-developed by AstraZeneca Plc and Bristol-Myers Squibb Company, has been recommended for approval in Europe. In January, the same drug was turned down by the FDA.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom